# Cancer Focus Fund

> Cancer Focus Fund is a VC fund in Shreveport backing Biotechnology and Medical. See 10 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Shreveport, United States
- Total investments: 10
- Last investment: Feb 2026
- Lead investor: 60%
- Fund size: $50M
- Last fund: Dec 2019
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/cancer-focus-fund/
- Website: https://cancerfocusfund.com

Cancer Focus Fund is an investment firm that is dedicated to providing financial services to its clients. The company was founded by Ross Barrett.

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $5.4M–$28M |
| Venture - Series Unknown | $4.5M–$47M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 50% |
| Medical | 3 | 30% |
| Health Care | 2 | 20% |
| Life Science | 2 | 20% |
| Therapeutics | 2 | 20% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Venture - Series Unknown | 4 | 40% |
| Series A | 3 | 30% |
| Seed | 1 | 10% |
| Series B | 1 | 10% |
| Funding Round | 1 | 10% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Israel | 3 | 30% |
| United States | 2 | 20% |
| Germany | 1 | 10% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Starget Pharma | Starget Pharma develops a new generation of targeted radiopharmaceutical technologies for the treatment of solid tumors. Starget Pharma has a pipeline of novel targeted radiopharmaceutical molecules that act as a vector for selectively transferring radioisotopes to cancer tumor tissues. | $18M | Series A | Feb 18, 2026 |  |
| KAHR medical | KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $22M | Series B | Oct 15, 2025 |  |
| Starget Pharma | Starget Pharma develops a new generation of targeted radiopharmaceutical technologies for the treatment of solid tumors. Starget Pharma has a pipeline of novel targeted radiopharmaceutical molecules that act as a vector for selectively transferring radioisotopes to cancer tumor tissues. | $5.1M | Venture - Series Unknown | Oct 23, 2024 |  |
| March Biosciences | March Biosciences is a clinical-stage cell therapy company that focuses on developing CAR-T cell strategies to address hematological cancers. | $28.4M | Series A | Oct 23, 2024 |  |
| Eisbach Bio | Eisbach Bio is a biotechnology company that creates new drugs that target molecular vulnerabilities in cancer genomes. Screening and cellular platforms are yielding first-in-class inhibitors to directly target the key vulnerability found in genetically defined tumors. It is founded in 2019 and is based in Martinsried, Bavaria. | $4.5M | Venture - Series Unknown | Mar 21, 2024 |  |
| March Biosciences | March Biosciences is a clinical-stage cell therapy company that focuses on developing CAR-T cell strategies to address hematological cancers. | $4.8M | Seed | Nov 09, 2023 |  |
| ImmunoGenesis | ImmunoGenesis develops science-driven immune therapies specifically designed to treat tumors lacking activated T cells or having other immune resistance mechanisms. | $4.5M | Venture - Series Unknown | Jun 27, 2023 |  |
| Nectin Therapeutics | Nectin Therapeutics is developing novel monoclonal antibodies directed towards members of the Nectin family of receptors and ligands that have major roles in the immune checkpoint mechanisms relevant for cancer immune therapy. These novel antibodies are developed for the treatment of solid and hematological malignancies. | $5.4M |  | Mar 07, 2022 |  |
| Nectin Therapeutics | Nectin Therapeutics is developing novel monoclonal antibodies directed towards members of the Nectin family of receptors and ligands that have major roles in the immune checkpoint mechanisms relevant for cancer immune therapy. These novel antibodies are developed for the treatment of solid and hematological malignancies. | $5.4M | Series A | Mar 07, 2022 |  |
| KAHR medical | KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $46.5M | Venture - Series Unknown | Jun 16, 2021 |  |

10 of 10 investments shown.

## Co-investors
- [Peregrine Ventures](https://shizune.co/investors/profile/peregrine-ventures) — VC Fund, 3 deals together
- [aMoon Fund](https://shizune.co/investors/profile/amoon) — VC Fund, 2 deals together
- [Flerie Invest](https://shizune.co/investors/profile/flerie-invest) — VC Fund, 2 deals together
- [Oriella Ltd.](https://shizune.co/investors/profile/oriella-ltd) — VC Fund, 2 deals together
- [4BIO Capital](https://shizune.co/investors/profile/4bio-capital-partners) — VC Fund, 1 deal together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Bossa Invest](https://shizune.co/investors/profile/bossanova-investimentos) — VC Fund
- [Almi Invest](https://shizune.co/investors/profile/almi-invest) — VC Fund
- [Korea Credit Guarantee Fund](https://shizune.co/investors/profile/korea-credit-guarantee-fund) — VC Fund

### Similar country
- [F6 Ventures](https://shizune.co/investors/profile/flat6labs) — VC Fund
- [Oqal](https://shizune.co/investors/profile/oqal) — VC Fund
- [Alesta Yatırım](https://shizune.co/investors/profile/alesta-girisim) — VC Fund

## Featured in investor lists
- [Biotech Investors in Israel](https://shizune.co/investors/biotech-investors-israel)
- [Biotechnology VC Funds in Middle East](https://shizune.co/investors/biotechnology-vc-funds-middle-east)
- [Biotech VC Funds in Middle East](https://shizune.co/investors/biotech-vc-funds-middle-east)
- [Biotech VC Funds in Israel](https://shizune.co/investors/biotech-vc-funds-israel)
- [Biotechnology Investors in Middle East](https://shizune.co/investors/biotechnology-investors-middle-east)
- [Biotech Investors in Middle East](https://shizune.co/investors/biotech-investors-middle-east)

## FAQ

### What does Cancer Focus Fund invest in?

Cancer Focus Fund invests primarily in Biotechnology, Medical and Health Care startups, most often at Venture - Series Unknown and Series A stage. Most of the 10 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Cancer Focus Fund's check size?

Cancer Focus Fund typically joins rounds of $5.4M–$28M at Series A and $4.5M–$47M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Cancer Focus Fund participates in.

### When did Cancer Focus Fund last invest?

The most recent investment recorded for Cancer Focus Fund closed in Feb 2026. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co